KRAS and colorectal carcinoma: The discrepancy of the MAPK and PI3K inhibitor preclinical studies using CRC cell lines and clinical trials outcome led us to question whether MAPK/PI3K signaling is commonly upregulated in human CRC with KRAS mutations.